Navigating the research-clinical interface in genomic medicine: analysis from the CSER Consortium
- PMID: 28858330
- PMCID: PMC5832495
- DOI: 10.1038/gim.2017.137
Navigating the research-clinical interface in genomic medicine: analysis from the CSER Consortium
Abstract
PurposeThe Clinical Sequencing Exploratory Research (CSER) Consortium encompasses nine National Institutes of Health-funded U-award projects investigating translation of genomic sequencing into clinical care. Previous literature has distinguished norms and rules governing research versus clinical care. This is the first study to explore how genomics investigators describe and navigate the research-clinical interface.MethodsA CSER working group developed a 22-item survey. All nine U-award projects participated. Descriptive data were tabulated and qualitative analysis of text responses identified themes and characterizations of the research-clinical interface.ResultsSurvey responses described how studies approached the research-clinical interface, including in consent practices, recording results, and using a research versus clinical laboratory. Responses revealed four characterizations of the interface: clear separation between research and clinical care, interdigitation of the two with steps to maintain separation, a dynamic interface, and merging of the two. All survey respondents utilized at least two different characterizations. Although research has traditionally been differentiated from clinical care, respondents pointed to factors blurring the distinction and strategies to differentiate the domains.ConclusionThese results illustrate the difficulty in applying the traditional bifurcation of research versus clinical care to translational models of clinical research, including in genomics. Our results suggest new directions for ethics and oversight.
Conflict of interest statement
Robert Green receives compensation for speaking or consultation to AIA, GenePeeks, Helix, Illumina, Ohana, Prudential, and Veritas, and is co-founder and advisor to Genome Medical, Inc. Pearl O’Rourke is on a Bioethics Advisory Committee for Takeda.
References
-
- National Institutes of Health. RFA-HG-10-017: Clinical Sequencing Exploratory Research (U01). https://grants.nih.gov/grants/guide/rfa-files/RFA-HG-10-017.html. Accessed 12 March 2017.
Publication types
MeSH terms
Grants and funding
- U01 HG006507/HG/NHGRI NIH HHS/United States
- U01 HG006485/HG/NHGRI NIH HHS/United States
- U24 HG007307/HG/NHGRI NIH HHS/United States
- R01 HG008605/HG/NHGRI NIH HHS/United States
- U01 HG006500/HG/NHGRI NIH HHS/United States
- U01 HG007307/HG/NHGRI NIH HHS/United States
- U01 HG006487/HG/NHGRI NIH HHS/United States
- R01 HG006600/HG/NHGRI NIH HHS/United States
- P20 HG007243/HG/NHGRI NIH HHS/United States
- T15 LM007442/LM/NLM NIH HHS/United States
- U01 HG007292/HG/NHGRI NIH HHS/United States
- UM1 HG007292/HG/NHGRI NIH HHS/United States
- R01 CA154517/CA/NCI NIH HHS/United States
LinkOut - more resources
Full Text Sources
Other Literature Sources
